(Q42925566)

English

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies

scientific article published on 26 August 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

based on heuristic

inferred from title

multiple myeloma

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efstathios Kastritis

object named as

E Kastritis

2

0 references

author name string

D Christoulas

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

M Migkou

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

M Gavriatopoulou

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

M Gkotzamanidou

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

M Iakovaki

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

C Matsouka

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

D Mparmparoussi

9

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

M Roussou

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

E Efstathiou

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

E Terpos

12

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

publication date

26 August 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1769-1778

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

https://scigraph.springernature.com/pub.10.1038/leu.2010.175

0 references

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

International uniform response criteria for multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Frequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transpla

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Testing standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Multiple myeloma in elderly patients: prognostic factors and outcome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma:: final time-to-event results from the SUMMIT trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Meeting the unmet needs in anticoagulant therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

21 January 2018

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance therapy with thalidomide improves survival in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

The impact of extramedullary disease at presentation on the outcome of myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2010.175

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2010.175

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Dimensions Publication ID

0 references

release_ttshax2yk5anxkgzmk2fp6tznu

1 reference

https://api.fatcat.wiki/v0/release/ttshax2yk5anxkgzmk2fp6tznu

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42925566&oldid=1973902020"